DBT Technologies, which currently has its Viaskin Peanut patch for allergy desensitization, has published its clinical-stage Phase Ib trial results in the Journal of Allergy and Clinical Immunology.
The results show a favorable tolerability profile for about 96 percent of patients taking part in the study. The study was co-authored by Dr. Stacie Jones, Professor of Pediatrics at the University of Arkansas for Medical Sciences, Chief of Allergy and Immunology and Dr. and Mrs. Leeman King Chair in Pediatric Allergy at Arkansas Children’s Hospital in Little Rock.
The study was initially completed in February 2012
and carried forward into another study in 2014 and is now undergoing its third phase in a global randomized, double-blind, palcebo-controlled trial.
One hundred individuals between the ages of six and 50 were enrolled in this randomized, double-blind, placebo-controlled Phase Ib trial at five clinical sites in the United States. The trial had no adverse events or epinephrine use during treatment in the trial, even among those with documented severe reactions before the study began.